北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学临床肿瘤学院  > 胃肠肿瘤中心  > 期刊论文
学科主题: 临床医学
题名:
Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer
作者: Li, Fang-Hua1,2; Shen, Lin3; Li, Zhuang-Hua1; Luo, Hui-Yan1; Qiu, Miao-Zhen1; Zhang, Hui-Zhong4; Li, Yu-Hong1; Xu, Rui-Hua1
关键词: Cetuximab ; Metastatic colorectal cancer ; KRAS mutation ; Phosphatase and tensin protein expression
刊名: WORLD JOURNAL OF GASTROENTEROLOGY
发表日期: 2010-12-14
DOI: 10.3748/wjg.v16.i46.5881
卷: 16, 期:46, 页:5881-5888
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Gastroenterology & Hepatology
研究领域[WOS]: Gastroenterology & Hepatology
关键词[WOS]: GROWTH-FACTOR RECEPTOR ; TYROSINE KINASE INHIBITORS ; CELL LUNG-CANCER ; K-RAS MUTATIONS ; PLUS IRINOTECAN ; PHASE-II ; CHEMOTHERAPY ; OXALIPLATIN ; RESISTANCE ; EFFICACY
英文摘要:

AIM: To investigate the prognostic value of KRAS mutation, and phosphatase and tensin (PTEN) expression in Chinese metastatic colorectal cancer metastatic colorectal cancer (mCRC) patients treated with cetuximab.

METHODS: Ninety Chinese mCRC patients treated with cetuximab were evaluated for KRAS mutation and PTEN protein expression by DNA sequencing of codons 12 and 13 and immunohistochemistry, respectively. We then selected 61 patients treated with cetuximab, either in combination with chemotherapy, or alone as a second-line or third-line regimen to assess whether KRAS mutation or PTEN protein expression is associated with the response and the survival time of mCRC patients treated with cetuximab.

RESULTS: KRAS mutation was found in 30 (33.3%) tumor samples from the 90 patients, and positive PTEN expression was detected in 58 (64.4%) of the 90 patients. Among the 61 patients who were treated with cetuximab as a second-line or third-line regimen, the resistance to cetuximab was found in 22 patients with KRAS mutation and in 39 patients without KRAS mutation, with a response rate of 4.5% and 46.1% respectively (P = 0.001), a shorter median progression-free survival (PFS) time of 14 +/- 1.3 wk and 32 +/- 2.5 wk respectively (P < 0.001), a median overall survival (OS) time of 11 +/- 1.2 mo and 19 +/- 1.8 mo respectively (P < 0.001), as well as in 24 patients with negative PTEN expression and in 37 patients with positive PTEN expression respectively (P < 0.001), with a responsive rate of 4.2% and 48.6% respectively, a shorter median PFS survival time of 17 +/- 2.0 wk and 28 +/- 1.9 wk respectively (P = 0.07), and a median OS time of 11 +/- 1.3 mo and 18 +/- 1.9 mo respectively (P = 0.004). Combined KRAS mutation and PTEN expression analysis showed that the PFS and OS time of patients with two favorable prognostic factors were longer than those of patients with one favorable prognostic factor or no favorable prognostic factor (P < 0.001).

CONCLUSION: KRAS mutation and PTEN protein expression are significantly correlated with the response rate and survival time of Chinese mCRC patients treated with cetuximab. (C) 2010 Baishideng. All rights reserved.

语种: 英语
项目资助者: Program for New Century Excellent Talents in University
WOS记录号: WOS:000285448500014
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/58230
Appears in Collections:北京大学临床肿瘤学院_胃肠肿瘤中心_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, State Key Lab Oncol So China, Guangzhou 510060, Guangdong, Peoples R China
2.Shengli Oil Field Cent Hosp, Dept Med Oncol, Dongying 257034, Shandong, Peoples R China
3.Peking Univ, Sch Oncol, Dept GI Oncol, Beijing Canc Hosp & Inst, Beijing 100142, Peoples R China
4.Sun Yat Sen Univ, Ctr Canc, Dept Pathol, State Key Lab Oncol So China, Guangzhou 510060, Guangdong, Peoples R China

Recommended Citation:
Li, Fang-Hua,Shen, Lin,Li, Zhuang-Hua,et al. Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer[J]. WORLD JOURNAL OF GASTROENTEROLOGY,2010,16(46):5881-5888.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Li, Fang-Hua]'s Articles
[Shen, Lin]'s Articles
[Li, Zhuang-Hua]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Li, Fang-Hua]‘s Articles
[Shen, Lin]‘s Articles
[Li, Zhuang-Hua]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace